Analysis of durability of response to thalidomide treatment for relapsed myeloma patients

被引：3
|
作者：
Myers, B [1 ]
Dolan, G [1 ]
机构：
[1] Univ Nottingham Hosp, Queens Med Ctr, Dept Clin & Lab Haematol, Nottingham NG7 2UH, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2002年 / 118卷 / 01期
关键词：
thalidomide; myeloma; therapy; duration;
D O I：
10.1046/j.1365-2141.2002.03576_4.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：347 / 347
页数：1
相关论文
共 50 条
  • [21] Long term response and survival after thalidomide in relapsed/wrefractory multiple myeloma
    Zappasodi, P.
    Corso, A.
    Barbarano, L.
    Brasca, P.
    Petrucci, M. T.
    Calabrese, E.
    Palumbo, A.
    Bringhen, S.
    Pascutto, C.
    Mangiacavalli, S.
    Varettoni, M.
    Pica, G. M.
    Lazzarinu, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 137 - 137
  • [22] Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study
    Hovenga, S
    Daenen, SMGJ
    de Wolf, JTM
    van Imhoff, GW
    Kluin-Nelemans, HC
    Sluiter, WJ
    Vellenga, E
    ANNALS OF HEMATOLOGY, 2005, 84 (05) : 311 - 316
  • [23] Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study
    Sjoerd Hovenga
    Simon M. G. J. Daenen
    Joost T. M. de Wolf
    Gustaaf W. van Imhoff
    Hanneke C. Kluin-Nelemans
    Wim J. Sluiter
    Edo Vellenga
    Annals of Hematology, 2005, 84 : 311 - 316
  • [24] OPTIMUM Dose of Thalidomide for Relapsed Multiple Myeloma
    Kropff, Martin
    Baylon, Honorata Giongco
    Hillengass, Jens
    Robak, Tadeusz
    Hajek, Roman
    Liebisch, Peter
    Goranov, Stefan
    Hulin, Cyrille
    Blade, Joan
    Caravita, Tomaso
    Avet-Loiseau, Herve
    Moehler, Thomas M.
    Pattou, Claire
    Lucy, Lela
    Kueenburg, Elisabeth
    Glasmacher, Axel
    Zerbib, Robert
    Facon, Thierry
    BLOOD, 2009, 114 (22) : 396 - 396
  • [25] Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma:: better response rate with earlier treatment
    Maisnar, Vladimir
    Radocha, Jakub
    Buechler, Tomas
    Blaha, Vaclav
    Maly, Jaroslav
    Hajek, Roman
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2007, 79 (04) : 305 - 309
  • [26] Role of thalidomide in the treatment of patients with multiple myeloma
    Morgan, Gareth J.
    Davies, Faith E.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2013, 88 : S14 - S22
  • [27] Thalidomide treatment for relapsed/refractory multiple myeloma: A retrospective multicenter study.
    Bibas, M
    Andriani, A
    Ferrari, A
    Montanaro, M
    Niscola, G
    Recine, U
    Chierichini, A
    BLOOD, 2001, 98 (11) : 307B - 307B
  • [28] Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma
    Schmielau, J
    Teschendorf, C
    König, M
    Schmiegel, W
    Graeven, U
    LEUKEMIA & LYMPHOMA, 2005, 46 (04) : 567 - 569
  • [29] An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma
    Hus, I
    Dmoszynska, A
    Manko, J
    Hus, M
    Jawniak, D
    Soroka-Wojtaszko, M
    Hellmann, A
    Ciepluch, H
    Skotnicki, A
    Wolska-Smolen, T
    Sulek, K
    Robak, T
    Konopka, L
    Kloczko, J
    BRITISH JOURNAL OF CANCER, 2004, 91 (11) : 1873 - 1879
  • [30] An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma
    I Hus
    A Dmoszynska
    J Manko
    M Hus
    D Jawniak
    M Soroka-Wojtaszko
    A Hellmann
    H Ciepluch
    A Skotnicki
    T Wolska-Smolen
    K Sulek
    T Robak
    L Konopka
    J Kloczko
    British Journal of Cancer, 2004, 91 : 1873 - 1879
12345